Teva, P&G plan Indian venture; Novartis soothes Excedrin headache;

> In a joint venture, Proctor & Gamble ($PG) and Teva Pharmaceutical Industries ($TEVA) will reportedly invest $89 million to build a plant in Sanand, Gujarat, India, where Teva will make OTC products for the Vicks brand. Story

> Chris Viehbacher, CEO of Sanofi ($SNY), which closed a plant near Paris recently, says closing labs in Toulouse and Montpellier will be done "thoughtfully." Story

> The Senate took aim at the drug gray market, lashing out at some drug wholesalers and distributors it says are adding to the misery of drug shortages by "price gouging." Story
> A group of pain experts have asked the FDA to limit the claims and availability of opioids. Story

> Ingredientsmaker FMC BioPolymer says it will invest more than $100 million to build a new Avicel colloidal microcrystalline cellulose (MCC) manufacturing plant in Rayong, Thailand. Item

> GBI Research is predicting that the CMO market will more than double to $59.9 billion in 2018 as drugmakers outsource more work to Asia. Story

And Finally... In particularly good news for migraine sufferers, Novartis ($NVS) says on its Facebook page today that it has resumed production of Excedrin and it should return to store shelves in October. Story

Suggested Articles

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

AstraZeneca and Oxford BioMedica have inked a deal to produce commercial and clinical supply of the University of Oxford's COVID-19 shot hopeful.